Literature DB >> 1855991

Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution.

J H van de Wijgert1, A F Verheul, H Snippe, I J Check, R L Hunter.   

Abstract

This project investigated the effects of novel carriers and adjuvants on the isotype of murine immunoglobulin G (IgG) antibody to pneumococcal capsular polysaccharide type 14 (S14PS). S14PS conjugated to bovine serum albumin induced a weak antibody response which was 100% IgG1 following injection without adjuvant. The same polysaccharide conjugated to flagella of Salmonella typhi induced an antibody response which was 88% IgG3. S14PS-bovine serum albumin was injected with block copolymer L121 or Quil A in squalane-in-water emulsions. The copolymer L121 was at least as effective as Quil A or complete Freund adjuvant in inducing IgG antibodies. IgG1 was the dominant subclass for all. Addition of monophosphoryl lipid A, but not the threonyl derivative of muramyl dipeptide or nontoxic Rhodopseudomonas sphaeroides lipopolysaccharide, to copolymer L121 increased production of the IgG2a, IgG2b, and IgG3 subclasses. S14PS-flagella with copolymer L121 induced higher titers with a markedly altered isotype distribution: 13% IgG1, 52% IgG2a, 6% IgG2b, and 29% IgG3. Monophosphoryl lipid A added to L121 reduced IgG1 antibody to 5%, but increased IgG2a antibody to 14%, IgG2b antibody to 3%, and IgG3 antibody to 78%. These studies demonstrate that both the carrier and the adjuvant can influence the titer and isotype distribution of antipolysaccharide antibody responses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855991      PMCID: PMC258082          DOI: 10.1128/iai.59.8.2750-2757.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors.

Authors:  K Takayama; M Olsen; P Datta; R L Hunter
Journal:  Vaccine       Date:  1991-04       Impact factor: 3.641

2.  Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae.

Authors:  D E Briles; J L Claflin; K Schroer; C Forman
Journal:  Nature       Date:  1981-11-05       Impact factor: 49.962

3.  Trypanosoma cruzi: role of different antibody classes in protection against infection in the mouse.

Authors:  H A Takehara; A Perini; M H da Silva; I Mota
Journal:  Exp Parasitol       Date:  1981-08       Impact factor: 2.011

Review 4.  Preparation, properties, and applications of carbohydrate conjugates of proteins and lipids.

Authors:  J D Aplin; J C Wriston
Journal:  CRC Crit Rev Biochem       Date:  1981

5.  The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance.

Authors:  R Hunter; F Strickland; F Kézdy
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

6.  Properties of conjugated protein immunogens which selectively stimulate delayed-type hypersensitivity.

Authors:  J Coon; R Hunter
Journal:  J Immunol       Date:  1975-05       Impact factor: 5.422

7.  Pneumococcal vaccine in the United States. A critical analysis.

Authors:  J V Hirschmann; B A Lipsky
Journal:  JAMA       Date:  1981-09-25       Impact factor: 56.272

8.  Structural studies on the non-toxic lipid A from Rhodopseudomonas sphaeroides ATCC 17023.

Authors:  P V Salimath; J Weckesser; W Strittmatter; H Mayer
Journal:  Eur J Biochem       Date:  1983-10-17

9.  Measurement of the humoral immune response against Streptococcus pneumoniae type 14-derived antigens by an ELISA and ELISPOT assay based on biotin-avidin technology.

Authors:  A F Verheul; A A Versteeg; N A Westerdaal; G J Van Dam; M Jansze; H Snippe
Journal:  J Immunol Methods       Date:  1990-01-24       Impact factor: 2.303

10.  Subclass restriction of murine anti-carbohydrate antibodies.

Authors:  R M Perlmutter; D Hansburg; D E Briles; R A Nicolotti; J M Davie
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

View more
  6 in total

1.  Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.

Authors:  C Yang; W E Collins; J S Sullivan; D C Kaslow; L Xiao; A A Lal
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

2.  Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3.

Authors:  Dirk J Lefeber; Barry Benaissa-Trouw; Johannes F G Vliegenthart; Johannis P Kamerling; Wouter T M Jansen; Kees Kraaijeveld; Harm Snippe
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

3.  Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.

Authors:  A F Verheul; J A Van Gaans; E J Wiertz; H Snippe; J Verhoef; J T Poolman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

Review 4.  Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

Authors:  E AlonsoDeVelasco; A F Verheul; J Verhoef; H Snippe
Journal:  Microbiol Rev       Date:  1995-12

5.  Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin.

Authors:  R Schneerson; L Levi; J B Robbins; D M Bryla; G Schiffman; T Lagergard
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

Review 6.  New vaccines for the prevention of pneumococcal infections.

Authors:  H Käyhty; J Eskola
Journal:  Emerg Infect Dis       Date:  1996 Oct-Dec       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.